z-logo
Premium
MECHANISMS UNDERLYING NEBIVOLOL‐INDUCED ENDOTHELIAL NITRIC OXIDE SYNTHASE ACTIVATION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
Author(s) -
Ladage Dennis,
Brixius Klara,
Hoyer Heike,
Steingen Caroline,
Wesseling Andreas,
Malan Daniela,
Bloch Wilhelm,
Schwinger Robert HG
Publication year - 2006
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2006.04424.x
Subject(s) - enos , nebivolol , umbilical vein , nitric oxide , medicine , endocrinology , nitric oxide synthase , vasodilation , chemistry , nitric oxide synthase type iii , phosphorylation , endothelium , endothelial dysfunction , biology , biochemistry , in vitro , blood pressure
SUMMARY1 Nebivolol (NEB) has been shown to be a selective blocker of β 1 ‐adrenoceptors with additional vasodilating properties that are mediated, at least in part, by an endothelial‐dependent liberation of nitric oxide (NO). In the present study, we investigated the underlying mechanisms of NEB‐induced vasodilation. 2 Immunohistochemical staining of endothelial nitric oxide synthase (eNOS) was performed in the absence and presence of NEB in human umbilical vein endothelial cells (HUVEC). In addition, we measured the release of nitric oxide (NO) using diaminofluorescein. Metoprolol (MET) was used for comparison. 3 Nebivolol, but not MET (each at 10 µmol/L), caused a time‐dependent increase in NO release from HUVEC, as demonstrated by an increase in DAF fluorescence at 0 versus 10 min (+234 ± 7 and 55 ± 22% basal, respectively). Blockade of β 3 ‐adrenoceptors by SR 59230A (1 µmol/L) partially reduced the NEB‐induced increase in DAF fluorescence. Complete inhibition of NEB‐induced NO liberation was achieved by the simultaneous blockade of β 3 ‐adrenoceptors and oestrogen receptors (with 1 µmol/L ICI 182,780). 4 Application of NEB significantly increased eNOS translocation and serine 1177 phosphorylation of eNOS. However, NEB did not alter eNOS‐phosphorylation at threonine 495 and at serine 114. 5 In conclusion, the endothelium‐dependent NO liberation induced by NEB is due to stimulation of β 3 ‐adrenoceptors and oestrogen receptors and coincides with eNOS translocation and a phosphorylation at eNOS‐serine 1177. These characteristics of NEB may be beneficial not only when treating patients suffering from cardiovascular disease, but may also prevent further deterioration of endothelial dysfunction.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here